Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Medical Laboratory Technology Journal

Blood Profile of Rattus Nurvegicus Exposed to HgCl2 and Received Combination of IR Bagendit Rice Leaves-Infused Water and Young Coconut Water Budi Santosa
Medical Laboratory Technology Journal Vol. 8 No. 2 (2022): December
Publisher : Poltekkes Kemenkes Banjarmasin Jurusan Analis Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (283.715 KB) | DOI: 10.31964/mltj.v8i1.472

Abstract

Mercury chloride (HgCl2) is widely used in industries; in fact, this chemical substance is deadly for health and causes various health problems, such as liver damage, kidney damage, and hematopoietic disorders, especially in erythropoiesis. This study aims to determine the blood profile in Rattus nurvegicus exposed to HgCl2 by combining IR Bagendit rice leaves-infused water and young coconut water. This study employed an experimental method to examine the positive control group exposed to HgCl2 and the negative control group receiving a placebo. Meanwhile, the treatment groups received a combination of IR Bagendit rice leaves-infused water in stratified compositions and young coconut water. The hematologic profile was examined using a hematologic analyzer, while the reticulocyte count was examined using wet and dry methods. The mean value of each group was tested using ANOVA. This study has successively obtained average levels of Hb (C+ 12,0;C- 14,2;T1 12,5;T2 12,9;T3 12,8), the erythrocyte count (C+ 6,52;C- 7,80;T1 1,44;T2 1,07;T3 7,32), levels of Ht (C+ 35,5;C- 42,9;T1 37,8;T2 37,9;T3 38,2), MCV (C+ 73,7;C- 79,9;T1 80,4;T2 78,7;T3 79,6), MCH (C+ 27,3;C- 29,9;T1 29,5;T2 28,5;T3 29,1), and MCHC (C+ 31,1;C- 34,2;T1 31,9;T2 33,3;T3 32,1), and the reticulocyte count (C+ 2,0;C- 1,2;T1 1,3;T2 1,1;T3 1,3). The significant differences in the groups are found in levels of Hb, Ht, MCV, and MCHC (p-value 0,00; 0,00; 0,03; 0,01). This study concludes that combining IR Bagendit rice leaves-infused water and coconut water could prevent blood profile exposure to HgCl2. Suggestions for further research to increase the intervention time and measure oxygen levels.
Evaluation in Hematology and BCR-ABL Molecular Profiles in Patients with Chronic Myeloid Leukemia Undergoing Tyrosine Kinase Inhibitor Therapy Muhammad Ihza Lisan Shidqi; Budi Santosa; Muhamad Muslim; Haitami Haitami
Medical Laboratory Technology Journal Vol. 8 No. 2 (2022): December
Publisher : Poltekkes Kemenkes Banjarmasin Jurusan Analis Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (284.462 KB) | DOI: 10.31964/mltj.v8i1.484

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative malignancy due to the formation of the BCR-ABL fusion gene in chronic myeloid leukemia. This condition causes excessive cell proliferation, resulting in an increase in the number of leukocytes. Tyrosine Kinase Inhibitor (TKI) is a first-line therapy that helps reduce the percentage of the Breakpoint Cluster Region–Abelson (BCR-ABL) fusion gene in patients with chronic myeloid leukemia. This study was conducted to determine evaluation in the hematological profiles (hemoglobin levels, leukocyte counts, platelet counts) and molecular BCR-ABL in patients with chronic myeloid leukemia before and after 12 months of tyrosine kinase inhibitors therapy. This analytic observational study was administered using a cross-sectional design to in analyzing the medical records of CML patients who underwent TKI therapy at the Sub Specialist Polyclinic of Internal Medicine Hematology Oncology Ulin Banjarmasin Indonesia Regional Hospital from March 2021-April 2022. Statistical test was performed which analysis results showed that 12-month tyrosine kinase inhibitor therapy could increase the hemoglobin levels, decrease leukocyte counts, platelet counts as well as decreasing the percentage of BCR-ABL gene fusion in patients with chronic myeloid leukemia. In conclusion, evaluation of tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia obtained significant differences in the hematological profiles and the molecular BCR-ABL. Further researchers are recommended to compare the type of tyrosine kinase inhibitor therapy between Imatinib and Nilotinib on the hematological and molecular profiles of BCR-ABL in patients with chronic myeloid leukemia with a larger sample count.